Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes

JDDG - Journal of the German Society of Dermatology

Volumn 9, Issue 11, 2011, Pages 953-967

  Schöfer, Helmut ^a   Bruns, Roswitha ^a   Effendy, Isaak ^a   Hartmann, Martin ^a   Jappe, Uta ^a   Plettenberg, Andreas ^a   Reimann, Holger ^a   Seifert, Harald ^a   Shah, Pramod ^a   Sunderkötter, Cord ^a   Weberschock, Tobias ^a   Wichelhaus, Thomas A ^a   Nast, Alexander ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BACITRACIN; CEFALEXIN; CEFAZOLIN; CHLORHEXIDINE; CLINDAMYCIN; CLIOQUINOL; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FLUCLOXACILLIN; FOSFOMYCIN; FUSIDIC ACID; LINEZOLID; MEZLOCILLIN; NEOMYCIN; OCTENIDINE; OXACILLIN; PENICILLIN G; PIPERACILLIN; POVIDONE IODINE; PSEUDOMONIC ACID; RETAPAMULIN; RIFAMPICIN; SULFADIAZINE SILVER; TEICOPLANIN; TRICLOSAN; TYROTHRICIN; UNINDEXED DRUG;

BACTERIAL COLONIZATION; BLISTER; CARBUNCLE; CELLULITIS; CONTACT DERMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE TRANSMISSION; FOLLICULITIS; FURUNCULOSIS; HERPES SIMPLEX; HUMAN; IMPETIGO; INCIDENCE; LYMPHANGITIS; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MUCOSAL DISEASE; NOSE MUCOSA; PARONYCHIA; PERIFOLLICULITIS; PHLEGMON; PYODERMA; REVIEW; SEBORRHEIC DERMATITIS; SENSITIZATION; SKIN ABRASION; SKIN ABSCESS; SKIN INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION; STAPHYLOCOCCUS LUGDUNENSIS; STAPHYLOCOCCUS SAPROPHYTICUS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; BACTERIOLOGICAL TECHNIQUES; CROSS INFECTION; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GERMANY; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUCOUS MEMBRANE; STAPHYLOCOCCAL SKIN INFECTIONS;

EID: 84055176790     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2011.07786.x     Document Type: Review

References (103)

1. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20. (Pubitemid 27359263)
2. Forte WC, Noyoya AM, de Carvalho Junior F F, Bruno S. Repeated furunculosis in adult male with abnormal neutrophil activity. Allergol Immunopathol (Madr). 2000;28:328-31. (Pubitemid 33709372)
3. Nishijima S, Namura S, Nakagawa M, Kurokawa I, Kawabata S. Sensitivity to antibacterials of Staphylococcus aureus isolated from different types of skin infections. J Int Med Res. 1997;25:1-7. (Pubitemid 27072949)
4. Morishita Y, Tada J, Sato A, To i Y, Kanzaki H, Akiyama H, Arata J. Possible influences of Staphylococcus aureus on atopic dermatitis - the colonizing features and the effects of staphylococcal enterotoxins. Clin Exp Allergy. 1999;29:1110-17. (Pubitemid 29359430)
5. Cho SH, Strickland I, Tomkinson A, Fehringer A P, Gelfand EW, Leung DY. Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model. J Invest Dermatol. 2001;116:658-63. (Pubitemid 32467642)
6. Scott E, Duty S, Callahan M. A pilot study to isolate Staphylococcus aureus and methicillin-resistant S aureus from environmental surfaces in the home. Am J Infect Control. 2008;36:458-60.
7. Rankin S, Roberts S, O'Shea K, Maloney D, Lorenzo M, Benson CE. Panton valentine leukocidin (PVL) toxin positive MRSA strains isolated from companion animals. Vet Microbiol. 2005;108:145-8. (Pubitemid 40726100)
8. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, Moellering RC, Ferraro MJ. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207-8. (Pubitemid 32718546)
9. Robert Koch-Institut. MRSA: Sekundäre Linezolidresistenz bei einem Patienten mit Beatmungspneumonie. Epidemiologisches Bulletin 2008;9:73-4.
10. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA, für die Studiengruppe. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. aus dem Jahre 2007. Antiinfectives Intelligence, Rheinbach. 2009.
11. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh G F, Perdreau-Remington F. Emergence of multidrugresistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008;148:249-57. (Pubitemid 351665484)
12. Wulf M, Voss A. MRSA in livestock animals - an epidemic waiting to happen? Clin Microbiol Infect. 2008;14:519-21. (Pubitemid 351639065)
13. Otto M. Staphylococcus epidermidis - the 'accidental' pathogen. Nat Rev Microbiol. 2009;7:555-67.
14. Speziale P, Visai L, Rindi S, Pietrocola G, Provenza G, Provenzano M. Prevention and treatment of Staphylococcus biofilms. Curr Med Chem. 2008;15:3185-95.
15. Spelman D. Fusidic acid in skin and soft tissue infections. Int J Antimicrob Agents. 1999;12 Suppl 2:59-66.
16. Alsterholm M, Flytstrom I, Bergbrant I-M, Faergemann J. Fusidic acid-resistant Staphylococcus aureus in impetigo contagiosa and secondarily infected atopic dermatitis. Acta Derm Venereol. 2010;90:52-57.
17. Bojar RA, Hittel N, Cunliffe WJ, Holland K T. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1 % nadifloxacin and 2 % erythromycin. Drugs. 1995;49 Suppl 2:164-67.
18. Korting HC. Bakterielle Erkrankungen. In: Braun-Falco O, Plewig G, Wolff HH: Dermatologie und Venerologie. 4. Aufl. Berlin, Heidelberg, New York: Springer, 1995:178-218.
19. Heise H, Box A. Is general discontinuation of sulfonamides in external therapy justified? Hautarzt. 2002;53:225-26. (Pubitemid 36090582)
20. Schnuch A. Do sulfonamides still retain a place in dermatological therapy?. Hautarzt. 2002;53:163-6. (Pubitemid 36090571)
21. Koning S, Verhagen A P, van Suijlekom-Smit LW, Morris A, Butler CC, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2004: CD003261.
22. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev. 2008: CD006216.
23. Bode LG, Kluytmans JA, Wertheim HF, Bogaers D, Vandenbroucke-Grauls CM, Roosendaal R, Troelstra A, Box AT, Voss A, van der Tweel I, van Belkum A, Verbrugh HA, Vos MC. Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. N Engl J Med. 2010;362:9-17.
24. Bodmann K F, Grabein B, und die Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2010. Paul-Ehrlich-Gesellschaft für Chemotherapie e. V., 2010. ISBN: 978-3-00-031623-4.
25. Bernard P. Management of common bacterial infections of the skin. Curr Opin Infect Dis. 2008;21:122-28. (Pubitemid 351641513)
26. Abeck D, Korting HC, Mempel M. Pyoderma. Hautarzt. 1998;49:243-52.
27. Kingston D, Seal DV. Current hypotheses on synergistic microbial gangrene. Br J Surg. 1990;77:260-64. (Pubitemid 20103756)
28. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine D P, Chambers HF, Tally F P, Vigliani GA, Cabell CH, Link AS, De Meyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
29. Gorwitz RJ. A review of communityassociated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2008;27:1-7.
30. Hair PI, Keam SJ. Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia. Drugs. 2007;67:1483-512. (Pubitemid 47028521)
31. Katz DE, Lindfield KC, Steenbergen JN, Benziger D P, Blackerby KJ, Knapp AG, Martone WJ. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by grampositive bacteria. Int J Clin Pract. 2008;62:1455-64.
32. Rehm SJ, Boucher H, Levine D, Campion M, Eisenstein BI, Vigliani GA, Corey GR, Abrutyn E. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillinresistant isolates. J Antimicrob Chemother. 2008;62:1413-21.
33. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35:3-12.
34. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis. 2009;49:935-41.
35. Arbeitskreis Krankenhaus-und Praxishygiene der AWMF. Maßnahmen beim Auftreten multiresistenter Erreger (AWMF-Register-Nr. 029-019). Hygiene und Medizin. 2009;7:287-92.
36. MRSA-net - Euregioprojekt. Letzter Zugriff: 07.04.2011, URL: http://www.mrsa-net.org.
37. Yasuda T, Yoshimura S, Katsuno Y, Takada H, Ito M, Takahashi M, Yahazaki F, Iriyama J, Ishigo S, Asano Y. Comparison of bactericidal activities of various disinfectants against methicillin-sensitive Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. Postgrad Med J. 1993;69 Suppl 3:66-9.
38. Gong JQ, Lin L, Lin T, Hao F, Zeng FQ, Bi ZG, Yi D, Zhao B. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol. 2006;155:680-87. (Pubitemid 44352546)
39. Baker BS. The role of microorganisms in atopic dermatitis. Clin Exp Immunol. 2006;144:1-9.
40. Matsui K, Wirotesangthong M, Nishikawa A. Percutaneous application of peptidoglycan from Staphylococcus aureus induces eosinophil infiltration in mouse skin. Clin Exp Allergy. 2007;37:615-22. (Pubitemid 46537737)
41. Arikawa J, Ishibashi M, Kawashima M, Takagi Y, Ichikawa Y, Imokawa G. Decreased levels of sphingosine, a natural antimicrobial agent, may be associated with vulnerability of the stratum corneum from patients with atopic dermatitis to colonization by Staphylococcus aureus. J Invest Dermatol. 2002;119:433-9. (Pubitemid 35001954)
42. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung D Y M. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol. 2003;171:3262-69. (Pubitemid 37093553)
43. Rieg S, Steffen H, Seeber S, Humeny A, Kalbacher H, Dietz K, Garbe C, Schittek B. Deficiency of dermcidinderived antimicrobial peptides in sweat of patients with atopic dermatitis correlates with an impaired innate defense of human skin in vivo. J Immunol. 2005;174:8003-10. (Pubitemid 40806311)
44. Guzik TJ, Bzowska M, Kasprowicz A, Czerniawska-Mysik G, Wojcik K, Szmyd D, Adamek-Guzik T, Pryjma J. Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clin Exp Allergy. 2005;35:448-55. (Pubitemid 40577236)
45. Hung S-H, Lin Y-T, Chu C-Y, Lee C-C, Liang T-C, Yang Y-H, Wang L-C, Chiang B-L. Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics. Ann Allergy Asthma Immunol. 2007;98:51-56. (Pubitemid 46106158)
46. Wollenberg A, Frank R, Kroth J, Ruzicka T. Proactive therapy of atopic eczema - an evidence-based concept with a behavioral background. J Dtsch Dermatol Ges. 2009;7:117-21.
47. Ritter von Rittershain G. Die exfoliative Dermatitis junger Säuglinge. Zentralzeitung für Kinderheilkunde. 1878;2:3-23.
48. Monday SR, Vath GM, Ferens WA, Deobald C, Rago JV, Gahr PJ, Monie DD, Iandolo JJ, Chapes SK, Davis WC, Ohlendorf DH, Schlievert PM, Bohach GA. Unique superantigen activity of staphylococcal exfoliative toxins. J Immunol. 1999;162:4550-59. (Pubitemid 29314854)
49. Veien NK. The clinician's choice of antibiotics in the treatment of bacterial skin infection. Br J Dermatol. 1998;139 Suppl 53:30-6. (Pubitemid 29003263)
50. Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med. 2000;6:1275-77.
51. Murray RJ. Recognition and management of Staphylococcus aureus toxin-mediated disease. Intern Med J. 2005;35 Suppl 2:106-19.
52. Abeck D, Strom K, Schnopp C, Korting H, Heeg K. Pyodermie - Ein interdisziplinäres Problem. Dt Ärztebl. 2001;98:2950-60.
53. Koning S, van Suijlekom-Smit LW, Nouwen JL, Verduin CM, Bernsen RM, Oranje A P, Thomas S, van der Wouden JC. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. BMJ. 2002;324:203-6. (Pubitemid 34107085)
54. Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol. 1998;139 Suppl 53:37-40. (Pubitemid 29003264)
55. Lappin E, Ferguson AJ. Gram-positive toxic shock syndromes. Lancet Infect Dis. 2009;9:281-90.
56. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis. 2009;49:1369-76.
57. Chuang Y-Y, Huang Y-C, Lin T-Y. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs. 2005;7:11-25. (Pubitemid 40444226)
58. Centers for Disease Control and Prevention. Case definition for public health surveillance. Morbidity and Mortality Weekly Report. 1990;39:38-9.
59. Akiyama H, Kanzaki H, Tada J, et al. Coagulase-negative staphylococci isolated from various skin lesions. J Dermatol 1998;25:563-68. (Pubitemid 28484048)
60. Aminzadeh A, Demircay Z, Ocak K, et al. Prevention of chronic furunculosis with low-dose azithromycin. J Dermatolog Treat. 2007;18:105-8. (Pubitemid 46801838)
61. Bahrain M, Vasiliades M, Wolff M, et al. Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillinresistant Staphylococcus aureus infections. Scand J Infect Dis. 2006;38:702-7. (Pubitemid 44144733)
62. Bass JW, Chan DS, Creamer KM, et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo. Pediatr Infect Dis J. 1997;16:708-10. (Pubitemid 27300709)
63. Bernard P, Jarlier V, Santerre-Henriksen A. Antibiotic susceptibility of Staphylococcus aureus strains responsible for community-acquired skin infections. Ann Dermatol Venereol. 2008;135:13-19. (Pubitemid 351981969)
64. Bisno AL, Stevens DL. Streptococcus pyogenes. In: Mandell GL, Bennett JE, Dolin R, (Hrsg.): Principles and practice of infectious diseases. 6th edition. Philadelphia: Elsevier Churchill Livingstone, 2005;2362-92.
65. Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect. 2001;48 Suppl A: 9-14.
66. Bradley S F. Methicillin-resistant Staphylococcus aureus: long-term care concerns. Am J Med. 1999;106:2-10; discussion: 48-52.
67. Colsky AS, Kirsner RS, Kerdel FA. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface. Arch Dermatol. 1998;134:1006-09. (Pubitemid 28385324)
68. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1992;36:287-90.
69. Domann E, Hossain H, Fussle R, et al. Rapid and reliable detection of multiresistent Staphylococcus aureus (MRSA) by multiplex PCR. Dtsch Med Wochenschr. 2000;125:613-18. (Pubitemid 30337095)
70. Dryden MS, Dailly S, Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect. 2004;56:283-86. (Pubitemid 38444080)
71. Espersen F. Resistance to antibiotics used in dermatological practice. Br J Dermatol. 1998;139 Suppl 53:4-8. (Pubitemid 29003259)
72. Finlay BB, Falkow S. Common themes in microbial pathogenicity revisited. Microbiol Mol Biol Rev. 1997;61:136-69. (Pubitemid 27283798)
73. Gilbert M. Topical 2 % mupirocin versus 2 % fusidic acid ointment in the treatment of primary and secondary skin infections. J Am Acad Dermatol. 1989;20:1083-87. (Pubitemid 19151520)
74. Glenn MJ, Bennett RG, Kelly A P. Acne keloidalis nuchae: treatment with excision and second-intention healing. J Am Acad Dermatol. 1995;33:243-46.
75. Gravet A, Couppie P, Meunier O, et al. Staphylococcus aureus isolated in cases of impetigo produces both epidermolysin A or B and LukE-LukD in 78 % of 131 retrospective and prospective cases. J Clin Microbiol. 2001;39:4349-56. (Pubitemid 33117122)
76. Harbarth S, Dharan S, Liassine N, et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1999;43:1412-16. (Pubitemid 29259335)
77. Headington J T. Cicatricial alopecia. Dermatol Clin. 1996;14:773-82. (Pubitemid 26322545)
78. Hiramatsu K. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan. Am J Med. 1998;104:7-10.
79. Hoeger PH. Topical antibiotics and antiseptics. Agents, spectrum, side effects. Hautarzt. 1998;49:61-47; quiz: 345.
80. Hoeger PH, Lenz W, Boutonnier A, et al. Staphylococcal skin colonization in children with atopic dermatitis: prevalence, persistence, and transmission of toxigenic and nontoxigenic strains. J Infect Dis. 1992;165:1064-68.
81. Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol. 1996;26:255-60. (Pubitemid 26197836)
82. Hoss DM, Feder HM. Addition of rifampin to conventional therapy for recurrent furunculosis. Arch Dermatol. 1995;131:647-48.
83. Huang SS, Platt R. Risk of methicillinresistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis. 2003;36:281-85. (Pubitemid 36169662)
84. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol. 2004;50:854-58. (Pubitemid 38685764)
85. Jappe U. Staphylokokken-Infektionen. In: Schöfer H, Baur-Beger S: Aktuelle Dermatologie für Dermatologen und dermatologisch Interessierte, 2010. URL: http://www.dermanet-online.de/buch/kapitel2-2/Kap-2-2-1.pdf.
86. Mertz PM, Marshall DA, Eaglstein WH, et al. Topical mupirocin treatment of impetigo is equal to oral erythromycin therapy. Arch Dermatol. 1989;125:1069-73. (Pubitemid 19193125)
87. Naber KG, Vogel F, Scholz H, et al. Rationaler Einsatz oraler Antibiotika in der Praxis. Chemother J. 1993;2:184-92.
88. Niebuhr M, Mai U, Kapp A, et al. Antibiotic treatment of cutaneous infections with Staphylococcus aureus in patients with atopic dermatitis: current antimicrobial resistances and susceptibilities. Exp Dermatol. 2008;17:953-57.
89. Plewig G, Jansen T. Acneiform dermatoses. Dermatology. 1998;196:102-7. (Pubitemid 28116055)
90. Plewig G, Kligman AM. Gram-negative folliculitis. In: Plewig G, Kligman AM, (Hrsg.): Acne and rosacea. 3rd edition. Berlin-Heidelberg: Springer 2000;513-9.
91. Robert Koch-Institut. Erstes Auftreten von MRSA mit verminderter Glykopeptidresistenz in Deutschland nachgewiesen. Epidemiologisches Bulletin. 1998;36:255-6.
92. Schöfer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20:6-15.
93. Shah PM, Kresken M, Höffken G. Einteilung der parenteralen Cephalosporine. Chemother J. 2009;18:252-3.
94. Smith KJ, Neafie R, Yeager J, et al. Micrococcus folliculitis in HIV-1 disease. Br J Dermatol. 1999;141:558-61. (Pubitemid 29448426)
95. Stalder J F, Fleury M, Sourisse M, et al. Comparative effects of two topical antiseptics (chlorhexidine vs KMn04) on bacterial skin flora in atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1992;176:132-4.
96. Stieler W, Senff H, Janner M. Folliculitis nuchae scleroticans-successful treatment with 13-cis-retinoic acid (isotretinoin). Hautarzt. 1988;39:739-42.
97. Sunderkotter C, Herrmann M, Jappe U. Antimicrobial therapy in dermatology. J Dtsch Dermatol Ges. 2006;4:10-27.
98. Suss K, Vennewald I, Seebacher C. Case report. Folliculitis barbae caused by Candida albicans. Mycoses. 1999;42:683-85. (Pubitemid 30053377)
99. Thestrup-Pedersen K. Bacteria and the skin: clinical practice and therapy update. Br J Dermatol. 1998;139 Suppl 53:1-3. (Pubitemid 29003258)
100. Waldvogel FA. Staphylococcus aureus. In: Mandell GL, Bennett JE, Dolin R, (Hrsg): Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th edition. Philadelphia: Churchill Livingstone, Chapter 183, 2000;2069-92.
101. Watcher MA, Wheeland RG. The role of topical agents in the healing of fullthickness wounds. J Dermatol Surg Oncol. 1989;15:1188-95. (Pubitemid 19286633)
102. Witte W, Braulke C, Cuny C, et al. Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis. 2005;24:1-5. (Pubitemid 40179124)
103. Witte W, Wiese-Posselt M, Jappe U. Community-based MRSA. A new challenge for dermatology. Hautarzt. 2005;56:731-38. (Pubitemid 41187646)